Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
National Cancer Institute Search for Clinical Trials
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Generic interferon-beta
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
European Medicines Agency
Biogen Reports Another Tecfidera PML Case
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Cognitive impairment in multiple sclerosis.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
TGN1412: From Discovery to Disaster.

Pages